About Spero Therapeutics (NASDAQ:SPRO)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600
Debt
Debt-to-Equity RatioN/A
Current Ratio11.29%
Quick Ratio11.29%
Price-To-Earnings
Trailing P/E Ratio-0.72
Forward P/E Ratio-2.87
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.98 million
Price / Sales92.53
Cash FlowN/A
Price / CashN/A
Book Value$5.91 per share
Price / Book2.16
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees35
Outstanding Shares14,370,000
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics (NASDAQ:SPRO) posted its quarterly earnings results on Monday, April, 2nd. The company reported ($1.59) EPS for the quarter, topping analysts' consensus estimates of ($1.77) by $0.18. The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $0.40 million. View Spero Therapeutics' Earnings History.
What price target have analysts set for SPRO?
5 equities research analysts have issued 12 month target prices for Spero Therapeutics' stock. Their forecasts range from $26.00 to $30.00. On average, they anticipate Spero Therapeutics' stock price to reach $27.6667 in the next year. View Analyst Ratings for Spero Therapeutics.
What are Wall Street analysts saying about Spero Therapeutics stock?
Here are some recent quotes from research analysts about Spero Therapeutics stock:
- 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (2/21/2018)
- 2. Cantor Fitzgerald analysts commented, "Differentiated pipeline addresses large unmet needs in infectious disease. Spero has three development programs that target multibillion-dollar commercial opportunities. The company’s drugs focus on unmet needs inside and outside the hospital setting. Spero plans to commercialize its products using an accelerated path to market, saving investors time and money. The company’s three leading drugs: 1) SPR994/oral carbapenem, which could be the first new oral therapy for cUTI in 21 years. Unlike competing drugs, SPR994 will be covered outside the hospital formulary, where it will not compete with generics and be part of the bundle. The drug is being developed for UTI, but could also be used for IAI, blood stream infections, and CAP; 2) SPR741 and SPR206/IV potentiators address major unmet needs in the hospital setting and expand the utility of existing antibiotics; and, 3) the SPR720/NTM program is a novel oral bacterial gyrase inhibitor designed to treat a rare lung infection." (2/8/2018)
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include CymaBay Therapeutics (CBAY), Homology Medicines (FIXX), Karyopharm Therapeutics (KPTI), Omeros (OMER), ANI Pharmaceuticals (ANIP), Dova Pharmaceuticals (DOVA), Arcus Biosciences (RCUS), BeyondSpring (BYSI), AMAG Pharmaceuticals (AMAG), Reata Pharmaceuticals (RETA), Rocket Pharmaceuticals (RCKT), Geron (GERN), Endocyte (ECYT), Rhythm Pharmaceuticals (RYTM) and Ziopharm Oncology (ZIOP).
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 37)
- Dr. Thomas R. Parr Jr., Ph.D., Chief Scientific Officer (Age 64)
- Mr. Joel D. Sendek, CFO & Treasurer (Age 51)
- Ms. Cristina Larkin, Chief Operating Officer (Age 48)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
When does the company's lock-up period expire?
Spero Therapeutics' lock-up period expires on Tuesday, May 1st. Spero Therapeutics had issued 5,500,000 shares in its public offering on November 2nd. The total size of the offering was $77,000,000 based on an initial share price of $14.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Has Spero Therapeutics been receiving favorable news coverage?
Headlines about SPRO stock have been trending somewhat positive this week, Accern reports. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spero Therapeutics earned a news impact score of 0.01 on Accern's scale. They also assigned media coverage about the company an impact score of 45.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $12.75.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $180.62 million and generates $1.98 million in revenue each year. The company earns $-38,740,000.00 in net income (profit) each year or ($17.82) on an earnings per share basis. Spero Therapeutics employs 35 workers across the globe.
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Spero Therapeutics (NASDAQ:SPRO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Spero Therapeutics in the last 12 months. Their average twelve-month price target is $27.6667, suggesting that the stock has a possible upside of 116.99%. The high price target for SPRO is $30.00 and the low price target for SPRO is $26.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 2.80 | 2.80 | 2.75 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.6667 | $27.6667 | $28.00 | N/A |
| Price Target Upside: | 116.99% upside | 94.42% upside | 133.53% upside | N/A |
Spero Therapeutics (NASDAQ:SPRO) Consensus Price Target History
Spero Therapeutics (NASDAQ:SPRO) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Spero Therapeutics (NASDAQ:SPRO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/7/2015 | quarterly | $0.0150 | 2.97% | 9/16/2015 | 9/18/2015 | 10/7/2015 |
| 5/6/2015 | quarterly | $0.0150 | 3.49% | 6/17/2015 | 6/19/2015 | 7/7/2015 |
| 3/6/2015 | quarterly | $0.0150 | 4.44% | 3/18/2015 | 3/20/2015 | 4/7/2015 |
| 11/5/2014 | quarterly | $0.0150 | 3.59% | 12/17/2014 | 12/19/2014 | 1/6/2015 |
| 8/11/2014 | quarterly | $0.0150 | 3.23% | 9/17/2014 | 9/19/2014 | 10/7/2014 |
| 5/9/2014 | quarterly | $0.0150 | 2.38% | 6/18/2014 | 6/20/2014 | 7/7/2014 |
| 3/6/2014 | quarterly | $0.0150 | 2.4% | 3/19/2014 | 3/21/2014 | 4/7/2014 |
| 11/8/2013 | quarterly | $0.0150 | 2.79% | 12/17/2013 | 12/19/2013 | 1/6/2014 |
| 8/7/2013 | quarterly | $0.0150 | 3.68% | 9/17/2013 | 9/19/2013 | 10/7/2013 |
| 5/8/2013 | quarterly | $0.0150 | 3.9% | 6/12/2013 | 6/14/2013 | 7/5/2013 |
| 3/8/2013 | quarterly | $0.0150 | 3.95% | 3/20/2013 | 3/22/2013 | 4/5/2013 |
(Data available from 1/1/2013 forward)
Spero Therapeutics (NASDAQ SPRO) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 46.28%
Spero Therapeutics (NASDAQ SPRO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/6/2017 | Casper Breum | Director | Buy | 214,285 | $14.00 | $2,999,990.00 | |  |
| 11/6/2017 | Cristina Larkin | COO | Buy | 1,500 | $14.00 | $21,000.00 | | |
| 11/6/2017 | Joel Sendek | CFO | Buy | 5,000 | $14.00 | $70,000.00 | | |
| 11/6/2017 | Plc Glaxosmithkline | Major Shareholder | Buy | 428,571 | $14.00 | $5,999,994.00 | | |
| 3/11/2013 | Allen S Greene | CEO | Buy | 15,000 | $1.53 | $22,950.00 | | |
| 12/28/2012 | Zohar Ben-Dov | Major Shareholder | Buy | 22,693 | $1.19 | $27,004.67 | | |
| 12/24/2012 | Jack Fingerhut | President | Buy | 2,000 | $2.40 | $4,800.00 | | |
| 9/5/2012 | John J Gorman | Director | Buy | 4,600 | $1.90 | $8,740.00 | | |
| 8/30/2012 | Allen S Greene | CEO | Buy | 5,000 | $1.82 | $9,100.00 | | |
(Data available from 1/1/2013 forward)
Spero Therapeutics (NASDAQ SPRO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Wired News – CDC Publishes Dynavax’s HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly Report
finance.yahoo.com - April 25 at 9:05 AM |
 | Spero Therapeutics' (SPRO) Lock-Up Period Will Expire on May 1st
www.americanbankingnews.com - April 24 at 1:18 AM |
| Spero Therapeutics Inc (SPRO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 1:30 AM |
 | Eight presentations on SPR741 at ECCMID, collectively supporting its activity, safety and tolerability
globenewswire.com - April 16 at 8:58 AM |
| Spero Therapeutics (SPRO) PT Set at $27.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 12 at 10:23 AM |
| Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
finance.yahoo.com - April 12 at 9:52 AM |
 | Spero Therapeutics (SPRO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:48 PM |
| These Alphabet-Backed Biotech Startups Went Public In 1Q18
finance.yahoo.com - April 6 at 9:23 AM |
| Q1 2018 EPS Estimates for Spero Therapeutics Inc Increased by Oppenheimer (SPRO)
www.americanbankingnews.com - April 6 at 7:58 AM |
| FY2018 EPS Estimates for Spero Therapeutics Inc Reduced by Analyst (SPRO)
www.americanbankingnews.com - April 6 at 7:24 AM |
| Analysts Set Expectations for Spero Therapeutics Inc's FY2022 Earnings (SPRO)
www.americanbankingnews.com - April 5 at 8:46 AM |
| Oppenheimer Analysts Give Spero Therapeutics (SPRO) a $30.00 Price Target
www.americanbankingnews.com - April 4 at 8:04 AM |
| Spero Therapeutics misses by $0.24, beats on revenue
seekingalpha.com - April 3 at 9:19 AM |
| Spero Therapeutics (SPRO) Announces Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - April 3 at 7:46 AM |
| Spero Therapeutics (SPRO) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - April 2 at 9:11 PM |
| Spero Therapeutics (SPRO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:47 PM |
| Where Spero Therapeutics Inc’s (NASDAQ:SPRO) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 29 at 4:47 PM |
| Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Quarterly Sales of $400,000.00
www.americanbankingnews.com - March 29 at 10:40 AM |
| -$1.56 EPS Expected for Spero Therapeutics Inc (SPRO) This Quarter
www.americanbankingnews.com - March 27 at 5:53 AM |
| Spero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 1:44 AM |
| Oppenheimer Reaffirms Buy Rating for Spero Therapeutics (SPRO)
www.americanbankingnews.com - March 21 at 7:48 PM |
| Brokerages Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00
www.americanbankingnews.com - March 11 at 1:56 AM |
| VHCP Management II LLC Takes Position in Spero Therapeutics Inc (SPRO)
www.americanbankingnews.com - March 6 at 10:31 AM |
| AWM Investment Company Inc. Invests $4.11 Million in Spero Therapeutics Inc (SPRO) Stock
www.americanbankingnews.com - March 6 at 4:45 AM |
| Spero Therapeutics to Present at March Investor Conferences
finance.yahoo.com - March 1 at 8:53 AM |
| Spero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 1:52 AM |
| $400,000.00 in Sales Expected for Spero Therapeutics Inc (SPRO) This Quarter
www.americanbankingnews.com - February 23 at 1:28 PM |
| Spero Therapeutics (SPRO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 21 at 1:42 PM |
| Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$1.56 Per Share
www.americanbankingnews.com - February 21 at 10:31 AM |
| Head-To-Head Survey: Aptevo Therapeutics (APVO) versus Spero Therapeutics (SPRO)
www.americanbankingnews.com - February 21 at 1:30 AM |
| Spero Therapeutics (SPRO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 14 at 12:32 PM |
| Spero Therapeutics Inc (SPRO) Forecasted to Post FY2018 Earnings of ($3.69) Per Share
www.americanbankingnews.com - February 14 at 10:46 AM |
| Spero Therapeutics (SPRO) Earns Overweight Rating from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - February 8 at 4:22 PM |
| Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00
www.americanbankingnews.com - February 6 at 10:40 AM |
| ValuEngine Upgrades Spero Therapeutics (SPRO) to "Sell"
www.americanbankingnews.com - February 4 at 12:48 PM |
| Analysts Expect Spero Therapeutics Inc (SPRO) to Announce -$1.56 Earnings Per Share
www.americanbankingnews.com - February 4 at 11:32 AM |
| Spero Therapeutics Inc (SPRO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:34 AM |
| Contrasting Spero Therapeutics (SPRO) and The Competition
www.americanbankingnews.com - February 1 at 11:06 PM |
| Spero Announces Appointment of David P. Southwell to its Board of Directors
finance.yahoo.com - February 1 at 9:29 AM |
| Zacks Investment Research Lowers Spero Therapeutics (SPRO) to Hold
www.americanbankingnews.com - January 31 at 12:45 PM |
| Spero Therapeutics (SPRO) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 30 at 3:18 PM |
| Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
finance.yahoo.com - January 29 at 4:10 PM |
| Zacks: Spero Therapeutics Inc (SPRO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 23 at 8:56 AM |
| Zacks: Analysts Expect Spero Therapeutics Inc (SPRO) Will Announce Quarterly Sales of $400,000.00
www.americanbankingnews.com - January 20 at 12:18 PM |
| Spero Therapeutics (SPRO) and Vital Therapies (VTL) Critical Contrast
www.americanbankingnews.com - January 16 at 3:10 PM |
| Analyzing Spero Therapeutics (SPRO) & Its Rivals
www.americanbankingnews.com - January 10 at 7:40 PM |
| Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
finance.yahoo.com - January 4 at 10:47 AM |
| Brokerages Set $24.00 Price Target for Spero Therapeutics, Inc. (SPRO)
www.americanbankingnews.com - December 28 at 5:50 AM |
| FY2017 EPS Estimates for Spero Therapeutics, Inc. Reduced by Analyst (SPRO)
www.americanbankingnews.com - December 20 at 6:54 AM |
| Spero Therapeutics (SPRO) Given a $30.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - December 18 at 11:18 PM |
Spero Therapeutics (NASDAQ:SPRO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Spero Therapeutics (NASDAQ:SPRO) Income Statement, Balance Sheet and Cash Flow Statement
Spero Therapeutics (NASDAQ SPRO) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
